This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

• ClinicalTrials.gov Identifier: NCT03635099
• Recruitment Status: Active, not recruiting
• First Posted: August 17, 2018
• Last Update Posted: September 4, 2019
• Sponsor: Boehringer Ingelheim
• Information provided by (Responsible Party): Boehringer Ingelheim

Study Description

Brief Summary:

The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives are to evaluate the safety of BI 730357 through 24 weeks of treatment, and the effects of dose escalation and longer treatment duration on efficacy

Condition or disease	Intervention/treatment	Phase
Psoriasis	Drug: BI 730357; Drug: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 180 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
• Actual Study Start Date: September 17, 2018
• Estimated Primary Completion Date: October 18, 2019
• Estimated Study Completion Date: February 7, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Dose group A	Drug: BI 730357; Film-coated tablet
Experimental: Dose group B	Drug: BI 730357; Film-coated tablet
Experimental: Dose group C	Drug: BI 730357; Film-coated tablet
Experimental: Dose group D	Drug: BI 730357; Film-coated tablet
Placebo Comparator: Dose group E	Drug: Placebo; Film-coated tablet

Outcome Measures

Primary Outcome Measures :

1. Achievement of ≥ 75% reduction from baseline PASI (Psoriasis Area and Severity Index) score (PASI 75) at Week 12 [ Time Frame: Up to Week 12 ]
2. Achievement of a sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 12 [ Time Frame: Up to Week 12 ]

Secondary Outcome Measures :

1. Achievement of ≥50% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI50) at Week 12 [ Time Frame: Up to Week 12 ]
2. Achievement of ≥90% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI90) at Week 12 [ Time Frame: Up to Week 12 ]
3. Achievement of 100% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI100) at Week 12 [ Time Frame: Up to Week 12 ]
4. Achievement of sPGA (Static Physician's Global Assessment) clear at Week 12 [ Time Frame: Up to Week 12 ]
5. Achievement of ≥75% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI75) at Week 16, 20, 24 [ Time Frame: Up to Week 24 ]
6. Achievement of an sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 16, 20, 24 [ Time Frame: Up to Week 24 ]
7. Change from baseline in psoriasis symptoms evaluated using the total score on the PSS (Psoriasis Symptoms Scale) at week 12 [ Time Frame: Up to Week 12 ]
8. Achievement of a Dermatology Life Quality Index (DLQI) score of 0 or 1 at Week 12 [ Time Frame: Up to Week 12 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female patients. Woman Of ChildBearing Potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly from date of screening until 4 weeks after last treatment in this trial. A list of contraception methods meeting these criteria is provided in the patient information.
• Age 18 to 75 years (both inclusive) at screening
• BMI < 35 kg/m2 at screening
• Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the patient

• Patients must be candidates for systemic PsO therapy.Moderate-to-severe plaque psoriasis:

  • BSA ≥10% and
  • PASI ≥12 and
  • sPGA moderate or severe
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion Criteria:

• Nonplaque forms of PsO (including guttate, erythrodermic, or pustular), current druginduced PsO (including a new onset or exacerbation of PsO from, e.g., beta blockers, calcium channel blockers, lithium), active ongoing inflammatory diseases (including but not limited to Inflammatory bowel disease (IBD)) other than PsO that might confound trial evaluations
• Previous enrolment in this trial or previous exposure to BI 730357.
• Currently enrolled in another investigational device or drug trial, or is less than 30 days (from randomisation) since ending another investigational device or drug trial(s), or is receiving other investigational treatment(s).

• Use of

  • any biologic agent within 12 weeks, or
  • any anti IL-23 biologic agent within 24 weeks prior to randomisation, or
  • systemic anti-psoriatic medications or phototherapy within 4 weeks prior to randomisation, or
  • topical anti-psoriasis medications within 2 weeks prior to randomisation
• Received a live vaccination within 12 weeks prior to randomisation (visit 2), or any plan to receive a live vaccination during the conduct of this trial
• Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
• Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled.
• Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial.
• Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to randomisation or planned within 12 months after screening, e.g., hip replacement
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial
• Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix
• Relevant chronic or acute infections including human immunodeficiency virus (HIV), viral hepatitis, candidiasis and tuberculosis. A patient can be re-screened if the patient was treated and is cured from the acute infection.
• Evidence of a current or previous disease (including known or suspected IBD, cardiovascular disease), or medical finding that in the opinion of the Investigator is clinically significant and would make the study participant unreliable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data.
• Any suicidal ideation, including grade 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
• Unwillingness to adhere to the rules of UV-light protection
• Further exclusion criteria apply

Contacts and Locations

  Show 31 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim

More Information

• Responsible Party: Boehringer Ingelheim
• ClinicalTrials.gov Identifier: NCT03635099 History of Changes
• Other Study ID Numbers: 1407-0030; 2017-004659-21 ( EudraCT Number )
• First Posted: August 17, 2018
• Last Update Posted: September 4, 2019
• Last Verified: September 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases